Implementation and 2-year outcomes of the first FDA-approved implantable apheresis vascular access device.

CONCLUSION: The PowerFlow Implantable Apheresis IV Port can achieve flow rates necessary for all apheresis therapies and is a promising alternative vascular access device for patients undergoing apheresis. PMID: 31483876 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31483876?dopt=Abstract

Source: Transfusion - September 3, 2019 Category: Hematology Authors: Gray KL, Steidley IG, Benson HL, Pearce CL, Bachman AM, Adamski J Tags: Transfusion Source Type: research

More News: Central Venous Catheterization | Hematology | Radiology | Study